KRAS and colorectal cancer: While AI-HOPE provided general pathway interrogation and subsequent agents focused on TGF-β, PI3K, and JAK-STAT signaling, AI-HOPE-RTK-RAS specifically targets the RTK-RAS axis—one of the most clinically actionable pathways in colorectal cancer—enabling direct exploration of alterations in KRAS, NRAS, BRAF, EGFR, and related noncanonical genes such as NF1 and MAPK3.